Jennison Associates LLC Has $1.27 Million Stock Holdings in Haemonetics Corporation $HAE

Jennison Associates LLC raised its position in Haemonetics Corporation (NYSE:HAE) by 86.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,536 shares of the medical instruments supplier’s stock after buying an additional 10,433 shares during the quarter. Jennison Associates LLC’s holdings in Haemonetics were worth $1,270,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kemnay Advisory Services Inc. bought a new stake in shares of Haemonetics in the fourth quarter valued at about $26,000. True Wealth Design LLC increased its position in Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares during the period. Leonteq Securities AG bought a new position in Haemonetics during the fourth quarter worth about $30,000. EverSource Wealth Advisors LLC increased its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in Haemonetics in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. BTIG Research reiterated a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a research note on Friday, June 26th. Barrington Research reduced their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. reduced their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

Haemonetics Trading Down 0.2%

HAE opened at $77.95 on Thursday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a 50-day simple moving average of $71.90 and a 200 day simple moving average of $66.10. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of 38.59, a P/E/G ratio of 1.57 and a beta of 0.52.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same period last year, the firm earned $1.24 EPS. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts predict that Haemonetics Corporation will post 5.21 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.